학술논문

Major diabetes-related vascular events do not improve glycaemic control in a population-based cohort of type 1 diabetic individuals.
Document Type
Article
Source
Scandinavian Journal of Clinical & Laboratory Investigation. Nov2009, Vol. 69 Issue 7, p748-751. 4p. 2 Charts, 1 Graph.
Subject
*DIABETES
*PEOPLE with diabetes
*CANCER patients
*CANCER treatment
*LIGHT coagulation
Language
ISSN
0036-5513
Abstract
Objective: It is known that sudden serious events alter life styles related to treatment efficiency, as for example in cancer patients. However, it has not been specifically addressed if a first-time diabetes-related clinical event has impact on glycaemic regulation. We therefore assessed this in a population-based cohort of patients with long-term type 1 diabetes. Methods: This study was based on a cohort of type 1 diabetes patients with at least 20 years duration of diabetes. Of the 460 patients from the original cohort still alive at 1 January 1994, all patients with a major first-time diabetes-related clinical event (limb amputation, blindness, stroke, cardiac event, or panretinal photocoagulation) and glycated haemoglobin (HbA1c) measurements before, 3 and/or 12 months after the event were included. Differences in HbA1c measurements before and after the event were tested with Wilcoxon's test. Results: A total of 64 patients with a major clinical event between 1994 and 2006 entered the study. Mean HbA1c measurements decreased from 8.8% at baseline to 8.6% at 3 months and 8.7% after 12 months, a non-significant decrease. In all event groups, glycaemic regulation was unaltered in the majority of the patients. Only a minority worsened or improved their regulation, and in all groups only non-significant changes were seen. Conclusions: Surprisingly, complication-related events did not improve glycaemic regulation in long-term type 1 diabetes patients. This is in contrast with the experience from other patient categories and shows how difficult it can be to alter glycaemic regulation in diabetes patients with stabilized disease. [ABSTRACT FROM AUTHOR]